ABOUT
About Mycenax
Management Team
Milestone
PRESS CENTER
News
Events
Videos
MYCENAX Express
INSIGHT
CDMO SERVICES
Druggability
Cell Line Development
Process Development
Analytical Methods
PIC/S GMP Production
Antibody-Drug Conjugates
Cell and Gene Therapy
Exosome Manufacturing Platform
Plasmid DNA Manufacturing
Aseptic Fill-Finish Services
Formulation Development
CAREERS
Join Us
Career Development
Welfare and Events
ESG
ESG
Corporate Governance
Stakeholders
Community Involvement
INVESTOR RELATIONS
Financial Information
Information of Shareholders
Major Shareholders
Investor Contact Information
SUPPORT
Contact
Sitemap
Privacy
Languages
Languages
Languages
繁中
English
日文
PRESS CENTER
新聞中心
PRESS CENTER
News
2025/05/22
Mycenax Partners to Establish Japan's Domestic Biosimilar Manufacturing Facilities
Mycenax Partners to Establish Japan's Domestic Biosimilar Manufacturing Facilities
Mycenax Partners to Establish Japan's Domestic Biosimilar Manufacturing Facilities
返回列表
BACK
相關消息
related news
2023/06/01
Construction Commencement of Mycenax Biotech's Cell Therapy Pilot Plant
2021/05/28
Mycenax becomes Taiwan’s first CDMO company to complete the CHO-S and CHOZN® GS Cell Line Development with the Beacon® Optofluidic System
2025/06/16
Mycenax Granted Exclusive Rights to RIN Institute’s Proprietary ADC Linker Patents for CDMO Services
2021/08/26
Mycenax Reports 2022 H1 EPS of NT$0.32 with business expansion from traditional biologics to allogeneic cell therapy and emerging biologics.
GO TOP
This website uses cookies to ensure you get the best experience on our website.
我們在網站上使用cookies以改善網站的功能和使用,並用於分析和廣告目的。如果您繼續使用本網站而未變更您的cookies設置,則表示您同意我們使用cookies。
このウェブサイトはお客様のウェブ体験の向上のためにクッキーを使用しています。クッキーの使用に同意を頂ける場合は「同意」ボタンをクリックして下さい。
I agree.
我同意
同意する